Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles Schwab Corporation Common Stock (SCHW) vs Sanofi SA (SNY) Price & Performance

Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Charles Schwab Corporation Common Stock vs Sanofi SA — how do they compare? Charles Schwab Corporation Common Stock trades at $108.52 (market cap $186.25B), while Sanofi SA trades at $43.57 (market cap $104.30B). The key difference: Charles Schwab Corporation Common Stock is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

SCHWSNY
Market Cap
$186.25B$104.30B
Sector
FinancialsHealth
52-Week High
$108.02$52.34
52-Week Low
$85.35$41.33
Dividend Yield
1.19%5.55%
Enterprise Value
$124.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $108.63, up 0.59% today, approaching its all-time high of $109.05. The stock shows strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. Revenue grew to $23.92B in 2025 with net income margin expanding to 38.79%. Recent news highlights institutional buying and positive analyst coverage, though an insider sale and ongoing litigation present minor concerns.

Outlook remains positive with analyst consensus target of $122.33 suggesting 12.6% upside. Strong earnings growth, improving cash flow trends, and market leadership position support further appreciation. Key risks include market sensitivity to interest rates, competitive pressures, and potential regulatory impacts from ongoing litigation. The stock offers growth potential but requires monitoring of macroeconomic conditions.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY